Notably, our findings suggest that inclisiran’s effects are independent of lipid levels, reinforcing its potential as a therapeutic agent for cardioprotection in patients at high risk of heart failure, especially those undergoing sequential anthracycline and HER2-targeted therapies [45,46]. This evidence concerns the gene ERBB2 and heart failure.